Disrupting ART1 to interrupt the IL-6/STAT3 signalling axis may have therapeutic potential for improving CRC treatment efficacy, and the ART1-specific inhibitor MIBG has the potential to be an effective drug for this purpose. The gene discussed is ART1; the disease is colorectal carcinoma.